System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Valeria Santini is an expert in Hematology at Azienda Ospedaliero-Universitaria Careggi (Italy). As of October 2026, ScienceLeadR ranks Valeria Santini in the top 1% of experts worldwide for Anemia and Leukemia. Valeria Santini has authored 632 publications, the most recent in 2026, and is an investigator in 29 clinical trials, 7 of them ongoing. SLR score: 2,627 (community average: 125). How the SLR is computed.

LeadR Profile

Valeria Santini Azienda Ospedaliero-Universitaria Careggi Italy
2 627 ScienceLeadR Reputation 2627

Unlock

Register Login
Network Map

Hematology

Subspecialties: Oncology - Genetics

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1994 - 2026
Source: PubMed

Azienda Ospedaliero-Universitaria Careggi

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 632

Citations

Citations: 17 970 1st author: 71 Last author: 91 Unique author: 28

Main journals

Blood 186
Leuk Res 66
CL LYMPH MYELOM LEUK 40
J Clin Oncol 32
Haematologica 29

Best Journals

J Clin Oncol 21
N Engl J Med 3
Nat Med 3

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Validation of the International Working Group 2023 response criteria for higher risk myelodysplastic syndromes/neoplasms using the International Consortium for Myelodysplastic Syndromes VALIDATE database and a randomized phase III trial.
PMID 42845057 — myelodysplastic syndromes, hematology, neoplasms		Haematologica20260
Overall survival and long-term outcomes from the randomized, double-blind, placebo-controlled, phase III IMerge trial of imetelstat for lower-risk myelodysplastic syndromes.
PMID 42687814 — myelodysplastic syndromes, hematology		Haematologica20260
Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS).
PMID 42657925 — myelodysplastic syndromes, hematology, neoplasms, transplants, therapeutics		Am J Hematol20260
Evaluating response criteria in myelodysplastic/myeloproliferative neoplasms: a systematic review and meta-analysis.
PMID 42571225 — neoplasms		Blood Neoplasia20260
Comprehensive analysis of prognostic factors in myelodysplastic syndromes with isolated deletion of chromosome 5q.
PMID 42466989 — genes, myelodysplastic syndromes, chromosomes, mutation, prognosis		Blood Adv20260

Clinical Studies 29

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1 Study Chair: 1

By phase:

Phase 3 15
Phase 2 6
N/A 3
Phase 1/Phase 2 2
Phase 2/Phase 3 2
Phase 1 1

By status:

Completed 15
Active not recruiting 5
Recruiting 5
Terminated 4

By type:

Interventional 27
Observational 2

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 1
multicentric5to9 1
multicentricup10 23

Main Topics

Ongoing Clinical Trials

7 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A phase 3 trial comparing elritercept versus epoetin alfa for treatment of anemia due to lower risk MDS in ESA na ve adults who require RBC transfusions
2025-523544-12-00 — cells, epoetin alfa, myelodysplastic syndromes, safety, erythrocytes, blood, erythrocyte transfusion, anemia, neoplasms, blood cells, therapeutics		Phase 3Recruiting2026
1L LUSPA VS ESA IN NTD LOW RISK MDS PATIENTS
2022-500430-29-00 — epoetin alfa, myelodysplastic syndromes, safety, anemia, therapeutics, erythropoiesis		Phase 3Active not recruiting2023
A study with three treatments for higher risk chronic myelomonocytic leukaemia
2024-511102-22-00 — leukemia, myelomonocytic, chronic, leukemia, azacitidine, therapeutics		Phase 2Recruiting2025
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low Low or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
NCT07422480 — injections, cells, blood transfusion, epoetin alfa, myelodysplastic syndromes, safety, erythrocytes, blood, erythrocyte transfusion, anemia, pharmaceutical preparations, drug therapy, blood cells, therapeutics		Phase 3Recruiting2026
Study Evaluating Combination of Luspatercept in LR MDS Without RS Having Failed or Being Ineligible to ESA
NCT05181735 — injections, epoetin alfa, myelodysplastic syndromes, injections, subcutaneous		Phase 1/Phase 2Recruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS